C5 and paroxysmal nocturnal hemoglobinuria: Eculizumab, a complement C5 inhibitor used for the treatment of paroxysmal nocturnal hemoglobinuria, has demonstrated some efficacy in delaying disease progression, with the addition of treponistil becoming the mainstay of therapy for patients who develop systemic disease [19, 20].